CMBA
ALXN

C.M. Bidwell & Associates’s Alexion Pharmaceuticals ALXN Stock Holding History

C.M. Bidwell & Associates’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-734
Closed -$135K – 639
2021
Q2 		$135K Buy
+734
New +$126K 0.09% 217
2020
Q1 		– Sell
-1,300
Closed -$141K – 493
2019
Q4 		$141K Sell
1,300
-1,980
-60% -$212K 0.13% 142
2019
Q3 		$321K Buy
3,280
+20
+0.6% +$2.25K 0.32% 91
2019
Q2 		$427K Sell
3,260
-3,570
-52% -$460K 0.42% 68
2019
Q1 		$923K Buy
6,830
+3,420
+100% +$425K 0.92% 15
2018
Q4 		$332K Buy
3,410
+3,160
+1,264% +$374K 0.36% 77
2018
Q3 		$35K Hold
250
– – 0.03% 256
2018
Q2 		$31K Buy
+250
New +$29.2K 0.03% 275

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

C.M. Bidwell & Associates's ALXN Position: Q3 2021 in Review

C.M. Bidwell & Associates sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 734 shares — an estimated $135K sold.

C.M. Bidwell & Associates first reported a position in ALXN in Q2 2018 and held it in 8 quarters. The position peaked at $923K in Q1 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • C.M. Bidwell & Associates reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 734 Alexion Pharmaceuticals shares in Q3 2021, an estimated $135K.
  • C.M. Bidwell & Associates first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 8 quarters.
  • C.M. Bidwell & Associates's Alexion Pharmaceuticals position peaked at $923K in Q1 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2021, filed 12 Nov 2021.